112 related articles for article (PubMed ID: 30281285)
1. Reduction of Cisplatin-Induced Ototoxicity without Compromising Its Antitumor Activity.
Surnar B; Kolishetti N; Basu U; Ahmad A; Goka E; Marples B; Kolb D; Lippman ME; Dhar S
Biochemistry; 2018 Nov; 57(46):6500-6513. PubMed ID: 30281285
[TBL] [Abstract][Full Text] [Related]
2. The prodrug platin-A: simultaneous release of cisplatin and aspirin.
Pathak RK; Marrache S; Choi JH; Berding TB; Dhar S
Angew Chem Int Ed Engl; 2014 Feb; 53(7):1963-7. PubMed ID: 24453035
[TBL] [Abstract][Full Text] [Related]
3. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
[TBL] [Abstract][Full Text] [Related]
5. GMDTC Chelating Agent Attenuates Cisplatin-Induced Systemic Toxicity without Affecting Antitumor Efficacy.
Ge Y; Zheng N; Chen X; Zhu J; Sun W; Olson JR; Aga DS; Hu W; Tang X; Ren X
Chem Res Toxicol; 2019 Aug; 32(8):1572-1582. PubMed ID: 31240907
[TBL] [Abstract][Full Text] [Related]
6. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer.
Basudhar D; Cheng RC; Bharadwaj G; Ridnour LA; Wink DA; Miranda KM
Free Radic Biol Med; 2015 Jun; 83():101-14. PubMed ID: 25659932
[TBL] [Abstract][Full Text] [Related]
8. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
9. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
10. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
[TBL] [Abstract][Full Text] [Related]
11. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
[TBL] [Abstract][Full Text] [Related]
14. Anemoside B4 attenuates nephrotoxicity of cisplatin without reducing anti-tumor activity of cisplatin.
He L; Zhang Y; Kang N; Wang Y; Zhang Z; Zha Z; Yang S; Xu Q; Liu Y
Phytomedicine; 2019 Mar; 56():136-146. PubMed ID: 30668334
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Bai L; Wang A; Zhang Y; Xu X; Zhang X
Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
18. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
[TBL] [Abstract][Full Text] [Related]
19. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
Yu T; Yang Y; Zhang J; He H; Ren X
Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
[TBL] [Abstract][Full Text] [Related]
20. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
